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ABSTRACT 
 
 
Amyotrophic Lateral Sclerosis (ALS) is a relentless disease in which motor 
neurons degenerate, leading to paralysis and death.   Ten percent of ALS cases 
are familial, and mutations in 27 different genes have been linked to the disease. 
The first gene in which mutations were identified was that encoding superoxide 
dismutase 1 (SOD1). More recently, mutations in several RNA-binding proteins 
have also been shown cause ALS.  Many of these proteins are involved in RNA 
splicing, most prominently TDP-43 and FUS/TLS. These RNA binding proteins 
are mislocalized to the cytoplasm in motor neurons and some glial cells, where 
they form insoluble inclusions. Depletion of RNA-binding proteins in the nucleus 
leads to improper splicing of RNA. An expanded repeat in the hexanucleotide 
repeat GGGCCC, found in the first intron of the C9ORF72 gene, has also been 
linked to ALS. This repeated sequence is translated into dipeptide repeat 
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proteins (DPR), which also form aggregates in the cytoplasm. Many experimental 
therapies have been tested to ameliorate symptoms in animal models of ALS.  
 
Astrocytes are the most abundant non-neuronal cells that have been shown to 
contribute to neurodegeneration in ALS. Astrocytic dysfunction leads to motor 
neuron degeneration, which may be mediated in part by downregulation of the 
glutamate transporter GLT1. The resulting extracellular glutamate causes 
excitotoxicity, which leads to motor neuron death. Other glial cells, like 
oligodendrocytes, have also been linked to ALS pathology. Oligodendrocytes’ 
main function is to myelinate axons, but a lesser-known function, that of providing 
metabolic support, has also been identified. Oligodendrocytes are rich in a 
monocarboxylate transporter, MCT1, which exports lactate out of 
oligodendrocytes and into axons.  In the spinal cord of ALS model mice, 
oligodendrocytes degenerate much earlier than MNs. Oligodendrocyte precursor 
cells (OPCs) quickly proliferate and differentiate into oligodendrocytes, which 
have a reduced level of MCT1. Consequently, these new immature 
oligodendrocytes are thought to provide insufficient metabolic support to motor 
neurons.  
 
In the present study, we transplanted lineage-restricted oligodendrocyte 
precursor cells into the cervical spinal cord of SOD1G93A mice to assess survival 
of cells, denervation of muscle fibers by axons of motor neurons, and forelimb 
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grip strength, a functional assay of muscle denervation. To date, we have not 
seen a significant decrease in grip strength between mice into which OPCs were 
transplanted and controls, although grip strength in both groups of mice 
increased during the first 30 days post-surgery.  This experiment is ongoing and 
the mice will be analyzed at later post-surgical time points, including the 
experimental endpoint at 160 days, when survival of spinal cord motor neurons 
will again be assayed.    
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INTRODUCTION 
 
Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease, is a fatal, 
rapidly progressive neurodegenerative disorder characterized by selective death 
of motor neurons. ALS claims the lives of patients within 2-5 years of the onset of 
disease symptoms (Robberecht & Philips, 2013).  Disease progression begins 
with paralysis of the lower limbs in most patients, due to denervation of muscles 
and degeneration of motor neurons, eventually leading to paralysis of the upper 
limbs and the diaphragm (Sabatelli et al., 2008). When respiration is 
compromised, patients are either put on a respirator or they succumb to the 
disease. ALS, like other neurodegenerative disorders, has various causes, some 
of which are yet to be identified (Robberecht & Philips, 2013). Only 10% of the 
cases are familial. The first gene that was identified in familial cases of ALS was 
the gene encoding superoxide dismutase 1 (SOD1), mutations in which account 
for 20% of these cases (Robberecht & Philips, 2013).  
 
Wild type SOD1 is an enzyme that breaks down superoxide radicals, dangerous 
byproducts of oxidative phosphorylation within mitochondria (Bosco et al., 2010). 
Mutant forms of SOD1 protein (mSOD1) are misfolded, promoting its aggregation 
in cytoplasmic inclusions (Robbercht & Philips, 2013). The appearance of protein 
aggregates is correlated with and thought to be critical for the initiation and 
progression of motor neuron degeneration (Bosco et al., 2010). Although 
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pathogenic SOD1 mutations induce misfolding, the enzymatic activity or lack 
thereof is unrelated to the toxicity of the mutant protein (Munch et al., 2011). 
Improper post-translational modifications of  WT SOD1 also induce toxicity 
resembling that induced by mSOD1 (Robberecht & Philips, 2013). Therefore, 
disease progression is not due to loss of SOD1 function, but rather is due to a 
dominant gain of toxicity. The misfolded SOD1 not only causes neuronal cell 
death, but motor neurons from individuals with ALS also accumulate free radicals 
that inhibit axonal transport (Bosco et al., 2010). 
 
In addition, the misfolded SOD1 is thought to induce misfolding of wild type 
SOD1 protein in neighboring motor neurons in a prion-like manner, which could 
hypothetically promote rapid progression of the disease (Teng et al., 2010; 
Munch et al., 2011). The misfolded SOD1 protein can be secreted by cells via 
exocyotsis and has been found in the cerebral spinal fluid (CSF) of ALS patients. 
The presence of extracellular SOD1 suggests that the protein can be secreted by 
cells; it could also be taken up by neighboring cells via pinocytosis. SOD1 
misfolding induced by exogenous misfolded protein is self-propagating, in a 
prion-like manner (Munch et al., 2011).  Of the 150 SOD1 mutations that are 
associated with ALS, only one is recessive (Robberecht & Philips, 2013).  
 
Mutations in the gene encoding TDP-43, an RNA-binding protein, cause familial 
ALS, and TDP-43 is found in cytoplasmic inclusions in motor neurons in most 
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cases of ALS, including sporadic cases (Lagier-Tourenne et al., 2012). More 
recently, however, mutations in 26 other genes have been shown to cause 
familial ALS; some of these mutations have also been found in a small 
percentage of sporadic ALS patients (Robberecht & Philips, 2013).   TDP-43 is 
an RNA and DNA binding protein normally localized to the nucleus where it has 
been shown to play a key role in transcription, mRNA splicing and transport. It 
has been proposed that TDP-43 specifically interacts with the spliceosome to 
regulate splicing of pre-RNAs. Mislocalization of TDP-43 in the cytoplasm leads 
to impaired alternative splicing and RNA processing of a large number of 
transcribed messages (Lagier-Tourenne et al., 2012). Improper splicing of 
mRNAs leads to translation of aberrant proteins, which tend to misfold and 
aggregate in the cytoplasm (Gitler, 2012). Transcripts that contain long introns, 
including some encoding synaptic proteins, are most susceptible to TDP-43 
mislocalization (Lagier-Tourenne & Cleveland, 2009; Lagier-Tourenne et al., 
2012).  
 
Similar to TDP43, FUS/TLS is an RNA-binding protein that regulates pre-mRNA 
splicing (Lagier-Tourenne et al., 2012). Mislocalization of FUS to the cytoplasm 
causes abnormal splicing of a large number of pre-mRNAs, especially those 
containing long introns. In particular, misspliced mRNAs from tissues with FUS 
mutations contain extra exons that normally are spliced out. This indicates that 
FUS functions to hide the extra introns during splicing. When misspliced mRNA 
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from cells with either FUS or TDP-43 mutations were compared, expression of 45 
genes were either up- or down-regulated by mutations in both TDP-43 and 
FUS/TLS (Lagier-Tourenne et al., 2012). Some of these 45 genes code for 
synaptic proteins. These findings demonstrate an important link between RNA 
processing and ALS (Lagier-Tourenne et al., 2012). Although cytoplasmic protein 
aggregates containing TDP-43 and other proteins are found in the motor neurons 
of all ALS patients, it is not yet clear how these aggregates may contribute to 
neuronal cell death. (Gitler, 2012; Robberecht & Philips, 2013) 
 
Recently, expansion of a hexanucleotide repeat, GGGCCC, in the first intron of 
the C9ORF72 gene has been identified as the most common mutation linked to 
familial ALS (Mori et al., 2013). A majority of the patients with this expanded 
repeat have inclusions containing TDP-43 in the cytoplasm of motor neurons and 
display classic signs of ALS (Taylor, 2013). Normally only 25 copies of the repeat 
are present in the gene, but in ALS patients, there are several hundred copies of 
the repeat (Mori et al., 2013). The expanded repeat sequence can be translated 
into dipeptide repeat (DPR) proteins, even though the RNA transcribed from the 
repeats lack an ATG translation start signal (Mori et al., 2013; Taylor, 2013). The 
expanded hexanucleotide repeats are translated into three different DPR 
proteins, Poly- (Gly-Ala), Poly- (Gly-Pro), and Poly- (Gly-Arg) (Mori et al., 2013). 
The DPR proteins form insoluble cytoplasmic aggregates. Patients with this 
mutation in the C9ORF72 gene have insoluble aggregates of the Poly-GA protein 
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in cerebellar neurons. These aggregates are associated with cerebellar atrophy, 
a novel finding seen only in patients with this mutation. The Poly-GA protein 
aggregates may be a precursor to TDP-43-containing aggregates in the motor 
neurons of sporadic ALS patients (Mori et al., 2013).  
 
Although many genetic mutations have now been correlated with ALS, SOD1 
remains prominent, due to its widespread presence in cytoplasmic inclusions 
(Papadeas et al., 2011). SOD1 inclusions have been identified in motor neurons 
and also in glial cells, most prominently in astrocytes (Papadeas & Maragakis, 
2009). Normal astrocytes serve a variety of trophic functions in motor neurons. In 
rodent models of ALS and in ALS patients, mutant astrocytes have been 
identified as one of the leading causes of motor neuron degeneration (Nagai et 
al., 2007; Papadeas et al., 2011).  In vitro and in vivo studies conclude that 
astrocytes release neurotoxic factors that selectively attack and kill motor 
neurons (Nagai et al., 2007; Papadeas et al., 2011).  Nagai et al. (2007) showed 
that cultured SOD1 mutant astrocytes killed both primary motor neurons (PMNs) 
and embryonic stem cell-derived motor neurons (ESMNs). SOD1 inclusions in 
the cytoplasm of PMNs only alter morphology, but the same inclusions in 
astrocytes had deleterious effects on morphology and survival of both PMNs and 
ESMNs. They also tested the selectivity of these toxic factors towards motor 
neurons compared to dorsal root ganglion neurons and interneurons, to which 
the astrocytes were not toxic. Their results suggested that the mutated SOD1 
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present in the astrocyte conferred a specific vulnerability upon the motor neuron 
(Nagai et al., 2007). 
 
Papadeas et al. (2011) confirmed the astrocyte-induced toxicity toward motor 
neurons in vivo. They unilaterally transplanted SOD1G93A glial-restricted 
precursor cells—cells that differentiate into mutant astrocytes—into the spinal 
cord of wild type rats. Transplanted SOD1G93A astrocytes induced motor neuron 
degeneration. Motor neuron death was also observed at a distance from the 
transplant site, which could have been caused by either microgliosis or astrocyte-
secreted toxic factors.  
 
Due to the strong correlation between astrocyte dysfunction and motor neuron 
death, and the challenges involved in motor neuron replacement, Lepore et al. 
(2008) used wild-type astrocyte replacement as a therapy. Glial-restricted 
precursor cells (GRPs)—astrocyte precursors—were transplanted into the 
cervical spinal cord of SOD1G93A rats. Cervical spinal cord was chosen due to its 
pools of respiratory motor neurons. These motor neurons are responsible for 
innervating the diaphragm, whose dysfunction precedes death in ALS patients. 
The study concluded with increased survivability and disease duration, mitigated 
motor neuron loss, decreased decline in motor function, and prolonged 
respiratory function. One of the primary, and most significant, findings of the 
study was a correlated loss of motor neurons in the same areas that showed 
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reduced expression of the primary astrocyte glutamate transporter, GLT1. 
Another group of neuronal proteins whose expression is altered by dysfunctional 
astrocytes is the dendritic glutamate (AMPA) receptors. Low expression of the 
AMPA receptors on the motor neuron render it more susceptible to excitotoxicity 
(Lepore et al., 2008). GRP transplantation ameliorates symptoms associated with 
dysfunctional astrocytes, most importantly, restoration of proper glutamate levels 
outside the cell (Lepore et al., 2008; Papadeas & Maragakis, 2009)  
 
Lepore et al. (2008) weren’t the first to test stem cell transplantation into the 
spinal cord as a potential therapy for ALS. Suzuki et al. (2007) engineered neural 
progenitor cells (hNPCs) to secrete glial-derived neurotrophic factor (GDNF) into 
the spinal cord, because GDNF cannot readily cross the blood-brain barrier. 
GDNF is retroactively transported to motor neuron cell bodies when delivered 
into muscle (Suzuki et al., 2008). Stem cells secreting GDNF greatly increased 
motor neuron survival in the pre-symptomatic stages of the disease; even at end 
stage, GDNF-secreting cells transplanted into the spinal cord maintained survival 
of over 30% of motor neurons (Suzuki et al., 2007; Ferraiuolo et al., 2013). 
Although GDNF secretion did not prevent astrogliosis, some mutant motor 
neurons (with SOD inclusions) survived in the highly toxic environment. Robust 
survival of the hNPCs and secretion of GDNF supported motor neuron survival, 
but these motor neurons did not maintain their synaptic connections with muscle 
cells. Hence, GDNF secretion into spinal cord did not help ameliorate  paralysis 
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in the ALS model rats (Papadeas & Maragakis, 2009; Suzuki et a., 2008; 
Ferraiuolo et al., 2013).  
 
However, GDNF expressed in muscle is retroactively transported to motor 
neuron cell bodies. Suzuki et al. (2008) engineered human mesenchymal stem 
cells (hMSCs) to secrete GDNF in muscles of SOD1 rats..  The transplanted 
hMSCs secreting GDNF survived and secreted GDNF into the muscles. GDNF is 
necessary for proper neuromuscular junction (NMJ) formation (Suzuki & 
Svendsen, 2008). The stem cell-mediated release of GDNF increased the 
survival of not only NMJs, but also the motor neurons innervating them 
(Papadeas & Maragakis, 2009). Disease onset was not altered, but progression 
was slowed (Suzuki et al., 2008). The most important effect of this therapy was a 
28-day increase in the lifespan of ALS model rats  These results underscore the 
importance of preserving the neuromuscular junctions as well as the motor 
neuron cell bodies in ALS. 
 
In another promising stem cell transplantation study, Teng et al. (2012) 
transplanted mouse or human neural stem cells (hNSCs) into the spinal cord of 
SOD1 mutant mice at various ages. Mice in the presymptomatic stage of the 
disease (8-10 weeks old) received transplants of hNSCs into L2 or the C6, T10, 
L1, and L3 segments of the spinal cord. Survival in 30% of mice that received 
multi-segmental injections increased by up to 200 days, and 10% of mice 
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transplanted with mouse NSCs had an increased lifespan of one year (Teng et 
al., 2012; Ferraiuolo et al., 2013). Teng et al. attributed this remarkable result to 
neurotrophic factors such as GDNF and NGF that were released by the hNSCs.  
Stem cell transplants during the late stages of disease did not result in prolonged 
lifespan. Two clinical trials are currently in progress to test the efficacy and 
tolerability of hNSC transplants (Glass et al., 2012). Neural stem cells could be 
further engineered to release more trophic or anti-inflammatory factors 
(Ferraiuolo et al., 2013). Oligodendrocytes are glial cells whose primary function 
is to myelinate CNS axons (Philips et al., 2013). Other functions of 
oligodendrocytes are less well understood. Studies in mouse models of 
oligodendrocyte injury, such as Plp1-null mice, have demonstrated axonal loss 
without demyelination, indicating that oligodendrocytes also support axons 
though myelin-independent mechanisms (Lee et al., 2012). Oligodendrocytes 
also metabolically support motor neurons. Since axons are so tightly wrapped 
with myelin, not much transfer of nutrients can occur through the myelin (Lee et 
al., 2012). Metabolic support of axons is thought to occur at the nodes of 
Ranvier, where MCT1, a monocarboxylate transporter, is possibly located (Lee et 
al., 2012; Philips et al., 2013). This transporter shunts lactate into and out of 
axons, depending upon the relative concentrations in the oligodendroglia (Lee et 
al., 2012).  
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Decreased activity and abundance of MCT1 is thought to cause axonal 
dysfunction and eventually motor neuron degeneration in the spinal cord of ALS 
patients and the SOD1 mutant ALS rodent model (Lee et al, 2012: Phillips et al., 
2013). Lee et al. (2012) hypothesized that the downregulation of MCT1 would 
reduce axonal function, and would eventually cause motor neuron death. 
Inhibition or downregulation of the MCT1 in culture caused the death of 33% of 
neurons within three months (Lee et al., 2012). Lentiviral-induced downregulation 
of MCT1 in the cervical spinal cord led to death of motor neurons around the 
injection site. Activated microglia were also noticed in this area, and were 
probably the agents of degeneration. MCT1 is downregulated in the spinal cord 
of ALS  patients (Lee et al., 2012) 
 
In accordance with ALS pathology, cytoplasmic inclusions of either SOD1 and/or 
TDP43 have also been found in oligodendrocytes, which cause them eventually 
to die (Lee et al., 2012). As a compensatory mechanism, new oligodendrocyte 
precursor cells differentiate into mature oligodendrocytes late in the disease 
process ( Lee et al., 2012 ). Philips et al. (2013) hypothesized that these new 
oligodendrocytes cannot make up for the loss of MCT1 in cells that died and thus 
cannot provide enough lactate to keep the motor neurons alive. Long before 
motor neuron degeneration, these oligodendrocytes exhibit aberrant morphology 
and dysfunction (Lee et al., 2012). There is a noticeable increase in Caspase-3, 
an apoptosis inducer.   
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Oligodendrocyte precursor cells (OPCs) (or NG2+ cells) are the lineage-
restricted precursors to mature oligodendrocytes. These precursors differentiate 
within a restricted lineage; they only differentiate into oligodendrocytes in vivo 
(Kang et al., 2010). Due to the high turnover of immature precursor cells, the 
number of CC1+ oligodendrocytes (mature cells) does not diminish. The 
maintenance of CC1+ does not correlate with increased  myelin basic protein 
(MBP), required for myelin formation (Lee et al., 2012; Philips et al., 2013). The 
reduction in MCT1 in these new oligodendrocytes may be linked to the reduced 
myelination. Both in vitro and in vivo studies show that increased SOD1G93A 
expression significantly reduces MCT1 and GLT1 expression (Lee et al., 2012; 
Philips et al., 2013; Papadeas et al., 2011). Newly formed oligodendrocytes in 
the SOD1 mutant spinal cord contain cytoplasmic inclusions, which are thought 
to contribute to the widespread motor neuron degeneration that marks the ALS 
disease course.  
 
The first mutation associated with ALS was discovered in 1994. Today we know 
that mutations in at least 26 genes are associated with familial ALS, with new 
genes being discovered each year (Robberecht & Philips, 2012). However, an 
effective treatment option is not available yet. Because there are many different 
mechanisms involved in the disease, it is difficult to design a therapy that would 
be effective in most patients (Robberecht & Philips, 2012).. In this study, we 
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investigated transplantation of oligodendrocyte precursor cells (OPCs) into the 
spinal cord of SOD1G93A mutant mice. Oligodendrocyte precursor cells (OPCs 
derived from mouse ES cells and expressing GFP under the control of an OPC-
specific promoter) were transplanted into the cervical spinal cord of ALS mutant 
mice to determine the potential of normal OPCs to reduce neurodegeneration 
and motor neuron death. The potential clinical benefits of this therapy are 
improved mobility, a slowing of disease progression and extension in lifespan in 
ALS model mice. Since MCT1 expression is reduced in the endogenously 
differentiated SOD1 mutant oligodendrocytes, our goal is to introduce wild type 
precursor cells and to determine if they will help alleviate the symptoms 
associated with MCT1 reduction. 
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METHODS 
 
Oligodendrocyte precursor cells 
 
Mouse oligodendrocyte precursor cells (OPCs) expressing GFP under the control 
of the Olig2 promoter were differentiated and provided by Drs. Peng Jiang and 
Wenbin Deng of the University of California, Davis. Cells were differentiated from 
mouse embryonic stem cells expressing the Olig2-GFP construct (Xu and 
Gottlieb, 2004) as described by Jiang et al. (2010). Cells were maintained in 
DMEM/F12 medium (LifeTechnologies or Mediatech) containing 1% N2 
supplement, 2% B27 supplement (both from LifeTechnologies), 20-ng/ml bFGF 
(Millipore), 10 ng/ml PDGF-AA (Peprotech), 1 µM-purmorphamine (Cayman 
Chemical), and 1% antibiotic-antimycotic (LifeTechnologies).  The OPCs were 
cultured on 100 mm dishes coated with poly-L-ornithine (Sigma; Hu et al., 2009).  
Cells were passaged using TrypLE Express (LifeTechnologies) when they 
reached 80% confluency.  Expression of GFP was seen in 20-50% of the cells. 
The medium was changed every 2-3 days.  
 
Mice  
 
Male mice with the SOD1 G93A mutation on a C57BL6/J background [B6.Cg-Tg 
(SOD1*G93A) 1Gur/J] were purchased from Jackson Laboratories. In our study, 
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we used SOD1 mutant mice with a C57BL6/J genetic background, instead of the 
more commonly used C57/SJL hybrid mice, because the C57BL6/J mice show 
much less variability, leading to results that are more statistically valid (Mead et 
al., 2011). Each SOD1 male mouse was housed for trio breeding with two wild 
type C57BL6/J females for 14 days. The pups were genotyped by PCR of DNA 
samples prepared from tail snips taken at 17-21 days of age or ear punches 
taken after 21 days, using primers specific for the human SOD1 transgene. Pups 
were weaned at 21 days, if large enough to survive on their own. Small pups 
were genotyped before 21 days but not weaned until 28 days of age.  Tails of 
weaned pups were colored and each one was assigned an identification number. 
Once big enough, their tails were tattooed for permanent identification.  
 
Genotyping 
 
The G93A mutant human SOD1 gene was detected by PCR using DNA from tail 
snips. Tails were anesthetized for 5 minutes with a cream containing 2.5% 
lidocaine and 2.5% procaine (Fougera Pharmaceuticals). Using a stainless steel 
razor blade, 3-4 mm pieces were cut from the tails and each was collected in a 
1.5 mL centrifuge tube. Tissue was digested with Gitschier Buffer containing 10 
mg/ml proteinase K, and 2% β-mercaptoethanol (Sigma)) and the tubes were 
shaken at 55C for 5 hours in an Eppendorf Thermomixer. Samples were then 
incubated in boiling water for 5 minutes, mixed by vortexing 5-10 seconds and 
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centrifuged 5 minutes at 13,000 g. The samples were stored at -20 C, until 
needed.  
 
PCR 
Polymerase Chain Reaction (PCR) primers were specific for the G93A mutant 
human SOD1 transgene.  The forward (5'- CCA AGA TGC TTA ACT CTT GTA ATC 
AAT GGC -3') and reverse (5'- CAG CAG TCA CAT TGC CCA GGT CTC CAA CAT G 
-3') primers (Operon Biotechnologies) were used at 1 µM (of the 10 µM solution). 
Each reaction contained 5 ml of REDExtract-N-Amp™ PCR Ready Mix (Sigma) 
and, 2 µl of digested sample (DNA) in a total volume of 10 µl. A Biometra 
TGradient 050-800 thermal cycler was used.  DNA was initially denatured at 
940C for 3 minutes, followed by 35 cycles of annealing at 550C for 1 minute, 
extension at 720C for 1 minute and 5 seconds and denaturation at 940C for 30 
seconds. The PCR product of approximately 300-400 bp was detected by 
electrophoresis (15-20 min at 100V) in TAE Buffer in a 1% agarose gel 
containing 1 µg/ml of ethidium bromide submerged in TAE buffer. DNA bands 
were detected using a UV Transilluminator (Fisher Scientific). 
 
OPC Transplantation into spinal cord  
 
To prevent rejection of transplanted OPCs, SOD1 mice were injected 
subcutaneously with immunosuppressant (10 mg/kg of both rapamycin and FK-
506; LC Laboratories) daily for 7 days before surgery and thereafter. Mice were 
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given Baytril (100 mg/ml; Butler Animal Health) and Ibuprofen pediatric 
suspension ((source) 1-2 days prior to surgery and 5 days post-surgery.  The 
immunosuppressants were prepared in 25% DMSO and 25% ethanol, and an 
equal amount of Phosphate Buffered Saline (PBS; Sigma).  
 
To prepare the OPCs for transplantation, cultured cells were dissociated using 
TrypLE Express and viable cells were counted using a hemacytometer. Cells 
were diluted into Neurobasal medium (LifeTechnologies) and pelleted by 
centrifugation (1200 rpm, 5 min). Cells were resuspended in complete medium at 
a concentration of 7.5 X 104 cells/µl and stored on ice until needed.  
 
Prior to surgery, each mouse was anesthetized with an intraperitoneal injection of 
50-mg/kg ketamine and 2.5-mg/kg xylazine. After the mouse was partially 
anesthetized, the skin on its back was shaved with clippers and remaining hair 
was removed using a depilatory cream (Sally Hansen Hair removal cream). The 
mouse was placed on a warming blanket (Gaymar Industries) attached to a water 
heater and pump (Gaymar Industries). The mouse’s head was taped to a nose 
cone, and 1% O2 and 0.75% isoflurane were administered. The limbs were taped 
to the warming blanket. Betadine (Purdue Products) and ethanol wipes were 
applied to the shaved area three times to sterilize the skin. The animal was then 
covered with a sterile drape, the surgeon donned sterile gloves, and sterile tools 
were laid on a second sterile drape. 
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Cervical laminectomy at the C4-C5 levels was performed at 56-62 d of age, as 
described by Lepore and Maragakis (2011). Respiration rate was monitored 
every 15-20 min and anesthesia was adjusted to keep respiration at 80-150/min. 
Briefly, 1-2 cm midline incisions of the skin and back muscles were made. The 
spine was then exposed, paraspinous muscles were removed with rongeurs and 
the lateral muscles were cut away. The surgical site was exposed using 
retractors made of paper clips and string. The C4 and C5 spinal laminae were 
removed with rongeurs and the dura overlying the spinal cord was cut with fine 
forceps and micro-scissors. Bilateral injections were made into 4 sites just medial 
to the entry zone of dorsal roots. Each site was injected with 2 µl of a stem cell 
suspension (1.5 X 105/site) in cell culture medium, or medium alone as a control. 
Injections were made with a 10 µl Hamilton syringe with a 33-gauge needle 
attached (Hamilton Co.) after penetrating the spinal cord at a depth of 0.8 mm to 
deliver cells or medium into the ventral horn.  
 
Following injection of cells or medium into the cervical spinal cord, the mouse 
was sutured with 4-0 silk sutures (Select Medical). The skin was stapled with 7 
mm wound clips (Fine Science Tools). The mouse was removed from anesthesia 
and incubated at 93F for several hours before being returned to the animal 
holding room.  
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Daily Care of Post-Surgical Mice 
 
Post-surgical mice were closely monitored for several days after surgery. Weight, 
hydration level, and indications of pain were assessed daily. To manage post-
surgical pain, carprofen (source) was injected subcutaneously prior to surgery 
and for two additional days after surgery. Immunosuppression with rapamycin 
and FK-506 by daily subcutaneous injections continued until mice were perfused.   
 
Forelimb Grip Strength 
 
Forelimb grip strength was determined using a grip strength meter (Columbus 
Instruments).  Mice were allowed to grasp with their forelimbs a mesh of thin bars 
attached to a force gauge. They were held by the tail and pulled away from the 
meter until they animals released the bar. The maximum force was measured in 
grams. Grip strength was measured beginning 4 days after surgery and twice 
weekly until the experimental endpoint or perfusion.  
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Perfusion of Mice and Tissue Processing 
 
Mice were perfused transcardially with chilled 0.9% saline followed by 4% 
paraformaldehyde in 0.1 M sodium phosphate buffer, pH 7.4. The C4-C5 
segments of the spinal cord and triceps muscles were removed, incubated in 
fixative 24 h at 4C, then incubated in 30% sucrose In 0.1 M sodium phosphate 
buffer, pH 7.4, at 4C. The tissue was embedded in OCT medium and frozen at -
80C. Cross-sections of spinal cord (20 µm thickness) and longitudinal sections of 
triceps muscle (35 µm thickness) were made with a cryostat. Sections were 
collected on charged glass slides and stored at -80C for further analysis. 
 
Assessment of NMJ Innervation 
 
Mice were perfused as described above at 110-130 d. The triceps muscles were 
removed and cryopreserved. Muscles were cut into 35 µm longitudinal sections 
using a cryostat. Sections were collected on glass slides and stored at -80C. 
Muscle sections were blocked and permeabilized with tris-buffered saline (TBS), 
0.1% saponin, 2% normal goat serum. To visualize nerve terminals and axons, 
sections were labeled with monoclonal antibodies against the synaptic vesicle 
protein SV2 and neurofilament protein (SV2 ascites, 1:1000 and 2H3 
concentrate, 1:3000, Developmental Studies Hybridoma Bank) 1 h at room 
temperature. Sections were washed 3 times 5 min in TBS and incubated with 
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Alexa 488-goat anti-mouse secondary antibody (1:200, LifeTechnologies) and 
Alexa 594-alpha-bungarotoxin (1.5 µg/ml, LifeTechnologies) 1 h, washed 3 times, 
5 min in TBS, and coverslips were mounted onto sections using aqueous 
mounting medium (90% glycerol, 0.1 M Tris buffer, pH 9.0, and 6.25 g/l n-propyl-
gallate). Axons and NMJs were viewed with a flourescence micropscope 
(Olympus BX-51) and images were taken using an Olympus DP71 digital 
camera.  
 
For quantitative analysis, NMJs were classified based on the degree of 
innervation of postsynaptic acetylcholine receptor-rich endplates by nerve 
terminals. Endplates were classified as ‘innervated’ if there was nearly complete 
overlap with a nerve terminal, “denervated” if there was no overlap with a nerve 
terminal or “partially innervated” if there was only partial overlap with a nerve 
terminal.  
 
Assessment of GFP-labeled Oligodendrocyte precursor cell (OPC) survival 
and proliferation 
 
Mouse spinal cord was sectioned (20 µm thickness) using a cryostat. Some of 
those sections were used to label GFP with an anti-GFP antibody (1:200; 
Millipore) and Alexa 488-goat anti-rabbit secondary antibody (1:200; 
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LifeTechnologies). Sections were blocked 1 h in TBS with 2% goat serum and 
antibody labeling was performed using a similar protocol to that described above.  
 
Counting Motor Neurons 
 
Sections of spinal cord (20 µm thickness) were stained with cresyl violet. The 
slides were mounted with Permount and viewed with an Olympus BX51 
microscope using brightfield illumination. All neurons in the ventral horn, 
including neurons in hypaxial, lateral, and medial motor columns, with a longest 
dimension of >15 µm were counted in at least four sections, and the counts were 
averaged. 
 
Experimental Endpoint 
 
Disease endpoint was defined as the inability of a mouse to right itself within 20 
seconds of being placed on either side. After the onset of disease symptoms 
(usually hindlimb weakness), mice were weighed daily. Mice that had lost >10% 
of their pre-surgical weight were injected subcutaneously with 0.3 ml saline if 
they appeared dehydrated.  When a mouse reached experimental endpoint, it 
was perfused and the spinal cord was removed for sectioning and motor neuron 
counts, as described above. 
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RESULTS 
 
Reduction in GFP- Expressing Cells in Cultures of Oligodendrocyte 
Precursor Cells. 
 
The OPCs we used expressed GFP under the control of the Olig2 promoter (Xu 
and Gottlieb, 2004), which is specific for OPCs and immature oligodendrocytes.  
As the OPCs were passaged, the percentage of GFP-expressing cells dropped 
from 70-80% at passages 1 and 2 to 20-25% at passages 5-7 (Table 1). Most of 
the mice transplanted with OPCs received cells that were 20-50% GFP-positive. 
Many of the cells that did not express GFP in culture had multiple, short 
processes (data not shown), suggesting that many of the cells had differentiated 
into oligodendrocytes. 
 
Failure to Locate Transplanted Oligodendrocyte Precursor Cells in vivo 
 
At 2-4 weeks after transplantation, GFP-positive OPCs were not detected in 
sections of cervical spinal cord. Instead, autofluorescent cells were seen near the 
sites of transplantation (Figure 2).  These cells were found in both ventral horn 
and dorsal horn along the needle track.  They appeared fluorescent in both the 
green and red channels, indicating that the fluorescence was not due to GFP, but 
may have been an artifact of fixation of dead or dying cells. 
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One SOD1 mouse, which received OPCs, however, was perfused 2 days post-
surgery, at 62 days of age. Sections of spinal cord contained GFP-positive cells 
detected without antibody labeling, as seen in Figure 2.  
  
Neuromuscular Junctions Become Denervated in SOD1G93A Mice Nearing 
Endpoint 
 
A SOD1 mutant mouse used for breeding was perfused at 139 days of age. 
Staining of the triceps muscle revealed that over 90% of the neuromuscular 
junctions (NMJs) identified by labeling acetylcholine receptors with fluorescent 
bungarotoxin were denervated (Figure 3), as compared to 100% that were 
innervated in a WT mouse. Even with such widespread loss of NMJ innervation, 
this mouse appeared to be walking normally. 
  
Forelimb Grip Strength of Post-surgical Mice 
 
Forelimb grip strength was measured twice weekly in post-surgical mice 
transplanted with OPCs or medium, and their wild type littermates. Grip strength 
in the two groups of mice increased for 30 days after surgery (to 90 d of age), 
and then plateaued (Figure 3).  To date, grip strength has been measured until 
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120 d of age, but the expected decline has not yet been seen.  Endpoint in this 
strain is 160-165 days (data not shown). 
 
The Potential Survival of Stem Cells and NMJs 
 
As mice reach endpoint, they will be perfused and spinal cord sections will be 
stained to determine whether OPC transplantation increases motor neuron 
survival. The innervation of motor end plates in mice at 120-130 d will also be 
determined (Figures 4 and 5). Labeling of spinal cord sections with anti-GFP 
antibodies will be used to determine whether OPCs survived. Currently, the data 
are inconclusive, and we cannot yet determine whether transplanted OPCs slow 
the progression of denervation at NMJs, reduce degeneration of motor neurons, 
or prolong survival in SOD1 mutant ALS model mice (Table 3). 
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 Table 1. Reduction in percentage of GFP-positive cells with subsequent 
passage of oligodendrocyte precursor cells. Oligodendrocyte precursor cells 
(OPCs) were acquired from Dr. Peng Jiang (Jiang et al., 2012). The GFP-
expressing cells were enriched by fluorescence-activated cell sorting (FACS). At 
each passage, cells were evaluated for GFP expression using a fluorescence 
microscope.  A progressive decline in the percentage of GFP-expressing cells 
was observed as cells were passaged.  
 
Table 1 
Days in 
Culture  
Action or Condition of 
Cells 
Passage Confluency GFP% 
0 P0 cells cultured P0 0% -- 
1 Passaged cells in 1 
dish  
P1 30% 40-50% 
1 Changed medium in 
another dish 
P0 50% 50% 
3 Changed medium P1 50-70% 35-50% 
7 Passaged cells P2 90% 35-40%  
9 Almost all cells 
detached 
P3 -- 40% 
10  
Passaged 1 dish (all 
cells attached) 
 
P3P4 
 
60% 
 
30% 
11  
Changed Medium in 1 
dish 
 
P4 
 
70% 
 
30% 
12 Passaged confluent 
dish 
P4P5 90% 25% 
14 Changed medium P5 40 20% 
15 Passaged dish  P6 60% before 
passage 
20% 
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Table 2. Innervation of neuromuscular junctions in mice that received OPC 
transplants and controls. A total of 35 µm longitudinal sections of triceps 
muscles from mice that received either OPC cells or medium injections into 
cervical spinal cord were labeled with antibodies against the synaptic vesicle 
protein SV2 and neurofilament, and Alexa 594-α-bungarotoxinto identify nerve 
terminals and motor endplates of neuromuscular junctions (NMJs).  Sections 
were viewed with a fluorescence microscope and 60 endplates were scored as 
fully innervated (100% of endplate area innervated by nerve terminals), partially 
innervated or completely denervated. There is no significant difference between 
the NMJs (p>0.05).  	  	  
 
 
 
 
 
 Inner
vated 
MNs 
Partially 
Innervat
ed 
Denervated Innervated 
MNs 
Partially 
Innervated 
Denervated 
N 6 6 6 6 6 6 
Averag
e 
30 22.34 7.67 31.66 23.67 4.67 
Standar
d 
Deviati
on 
 
2.82 2.34 3.44 3.20 5.72 3.61 
SEM 1.15 0.95 1.41 1.31 2.33 1.48 
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Table 3. Cresyl violet staining of motor neurons in cervical spinal cord 
sections.  Sections of the C5 and C6 cervical spinal cord (20 µm thickness) were 
stained with cresyl violet. All neurons in the ventral horn, including motor neurons 
(MNs) in hypaxial, lateral, and medial motor columns, with a longest dimension of 
>15 µm were counted and the counts were averaged. LMC: lateral motor column. 
Two-Tailed Student’s t-tests  showed that LMC motor neurons were not 
significantly different between the groups, but the total MNs were significantly 
greater in section from the medium control (p = 0.00208). 
 
 
 
Mouse spinal cord 
Injected with  OPC 
cells 
Mouse spinal cord 
Injected with medium 
 
MNs of 
lateral 
motor 
column 
Total 
MNs 
MNs of 
Lateral 
Motor 
Column 
Total 
MNs 
N 6 6 6 6 
Average 20.25 70.83 21.08 78.83 
Standard 
Deviation 
 
3.57 2.54 2.18 4.02 
Standard Error of 
Mean 
1.46 1.04 0.89 1.64 
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A.  
B.  
 
Figure 1. GFP-positive cells in mouse spinal cord transplanted with OPCs.  
OPC cells expressing GPF were seen in the ventral spinal cord in a 62 d old 
mouse (2 d post-surgery. A: 20X  and B: 40X magnification (bar, 100 µm). GFP 
cells were seen along the transplantation sites.  
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Figure 2. Autofluorescent cells in the cervical spinal cord of a wild type 
mouse transplanted with OPCs. Fluorescence was seen both channels. Cells 
were localized near around the needle tracks. These cells did not appear to be 
GFP positive. 
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Figure 3. Comparison of grip strength in mice that received OPC 
transplants and medium controls.  Grip strength continually increased for 
approximately 30 days after surgery, followed by a decline or plateau. No 
significant difference was observed between the groups (p>0.05).  Error bars 
indicate SEM. 
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A.  B.  
C.  D.  
 
Figure 4. Comparison of triceps neuromuscular junctions (NMJ in a 79-day 
wild type mouse and a 139-day SOD1 mutant mouse. A, C: Sections were 
labeled with synapsin (SV2) and neurofilament (C2H3) antibodies, to identify 
nerve terminals and axons. B, D: acetylcholine receptors in motor endplates, 
labeled with Alexa-594-α-bungarotoxin. Nerve terminals were visible in 79 d WT 
triceps sections but not in the 139 d SOD1mutant mouse muscle. Most endplates 
in the SOD1 triceps were denervated at 139 d. 40X magnification. 
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A.  
B.  
 
Figure 5. Comparison of triceps neuromuscular junctions (NMJ) of a 79 d 
WT mouse, and 139 day SOD1 mouse with A: synapsin (SV2) and 
neurofilament (C2H3) antibodies were used to label nerve terminals and axons.  
B: acetylcholine receptors in motor endplates, labeled with Alexa-594-α-
bungarotoxin. 60X magnification. 
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Discussion 
 
Oligodendrocyte precursor cells expressing GFP were cultured and transplanted 
into the cervical spinal cord of SOD1 mice. A significant reduction in GFP-
expressing cells in OPC cultures was observed with subsequent passages. 
These GFP-positive OPCs were seen 2 days after transplantation into spinal 
cord, but GFP expressing cells were not detectable several weeks after 
transplantation. Muscles from mice transplanted with OPCs and controls were 
analyzed for denervation of neuromuscular junctions (NMJs).  Whereas about 
90% of NMJs were denervated in a forelimb muscle from a non-experimental 
SOD1 mouse at 139 days of age, experimental mice at 110 days also showed 
partial denervation of NMJs.  Transplantation of OPCs did not reduce 
denervation at this stage, but this will be monitored as the disease progresses.  
Grip strength measurements have also not shown a behavioral difference to date 
between mice that received OPCs and controls, but this measure will be used to 
determine if OPC transplantation reduces the decline in motor performance 
associated with motor neuron degeneration as the disease progresses.  Finally, 
time to disease endpoint will be evaluated and spinal cords from end stage mice 
will be analyzed to determine whether OPCs reduce degeneration of motor 
neuron cell bodies. 
 
To date, no significant difference in grip strength or NMJ innervation has been 
observed between the mice transplanted with OPCs and controls. Forelimb grip 
	   34	  
strength in both cohorts (cells and medium) steadily increased for 30 days after 
surgery (at 60-90 days of age), followed by a plateau in grip strength from 90 to 
115 days of age. We expect to see declining grip strength from 115 days until 
endpoint is reached at 160 days. Grip strength was used as a behavioral 
measure of muscle innervation and motor neuron function in SOD1 mutant rats 
by Lepore et al. (2008). In the weeks after they transplanted GRP cells into rat 
spinal cord, an increase in grip strength was not observed. However, their grip 
strength data shows that GRP transplantation delayed the decline in motor 
performance.  
 
The cells that we transplanted into the experimental mice were only 20-50% 
GFP-positive. In our collaborator’s laboratory, the cells were approximately 80% 
GFP-positive (Dr. Peng Jiang, personal communication), but in our hands, a 
progressive reduction in the percentage of GFP positive cells occurred as in 
subsequent passages, dropping from as much as 70-80% at passages 1-2 to 20-
25% at passages 5-7, as shown in Table 1.  Although we used the same medium 
components from the same suppliers as Jiang et al. (2010), perhaps there were 
subtle differences in our culture conditions. Since this reduction was unexplained, 
we continued our experiment to gather preliminary data for future experiments. 
The GFP-negative cells appeared morphologically similar to oligodendrocytes, 
small cells with several small, branched processes.  
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Spinal cord sections from 3-4 week post-surgical wild type mice contained 
autofluorescent cells (Figure 2). GFP-positive cells were only seen in the spinal 
cord of an experimental SOD1 mouse, which was perfused 2 days after surgery 
(Figure 1). The loss of GFP-positive cells in 3-4 week post-surgical mice may 
have been due to ineffective immunosuppression, differentiation of the OPCs into 
oligodendrocytes, overfixation with 4% paraformaldehyde. The ability of 
antibodies to bind to GFP can be reduced in tissue that is overfixed. To 
overcome this problem, we have performed antigen retrieval with citrate buffer, 
which should remove some aldehyde groups attached to the protein due to the 
fixative. However, GFP-positive cells were still not readily visible after this 
procedure, although the autofluorescence was diminished.  
 
Along with data from the spinal cord, we labeled the neuromuscular junctions of 
forelimb muscles (triceps) to assess the extent of their innervation (Table 2).  
Data from 2 post-surgical mice (one from each cohort) revealed no observable 
significant difference from mice transplanted with OPCs and medium. In the 
future, more mice will be perfused closer to the experimental endpoint (~160 d) to 
observe determine if OPCs slowed denervation of muscles.  
 
The experimental approach we proposed was originally two-fold. The first 
approach was stem cell transplantation, which was conducted and is currently 
ongoing. The second approach was electrotransfer gene therapy to express 
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growth factors in limb muscles. Due to the level of our funding, we were not able 
to conduct both of these experiments. Suzuki et al. (2008) showed that secretion 
of GDNF by stem cells transplanted into muscle increased motor neuron survival 
and preserved innervation of muscles in ALS model rats. We proposed to 
electoporate plasmid DNA encoding GDNF into the gastrocnemius (hindlimbs) 
and triceps (forelimbs) muscles of 35- to 50-day old mice. We proposed to 
measure muscle expression and transport of GDNF to motor neuron cell bodies. 
Controls would have included mice whose muscles were injected with plasmid 
but not electroporated, and mice whose muscles were electroporated in the 
absence of plasmid. We hypothesized that GDNF delivered by electrotransfer 
into limb muscles would delay or retard disease onset and progression, improve 
muscle strength, increase the number of surviving motor neurons that innervate 
the electroporated muscles, and increase the number of innervated NMJs in 
those muscles. If successful, the electroporation and stem cell transplant 
approaches would have been combined to determine whether these treatments 
had a synergistic effect. 
 
Delays in our experiment were largely caused by the need to do many pilot 
surgeries to perfect our surgical technique and the anesthesia protocol. The 
Institutional Animal Care and Use Committee (IACUC) initially required us to 
perform groups of 10 surgeries and to maintain the health of the animals for 14 
days. However, 50-60% of the mice in the initial pilot did not survive, for various 
	   37	  
reasons. However, the surgical technique and anesthesia protocol have now 
been improved and in the experiment described in this thesis, 80% survival of 
post-surgical animals was achieved. 
 
Stem cell therapy shows promise in ameliorating symptoms in ALS (Teng et al. 
2012). Their recent study shows that neural stem cells secrete several 
neurotrophic factors in culture and the cells contain the same factors after 
transplantation into the spinal cord. Teng et al. (2012) described many 
advantages of stem cell therapy for ameliorating symptoms associated with ALS. 
Stem cell therapy could enhance trophic factor secretion, and enhance targeting 
and enhance release of anti-inflammatory factors (Ferraiuolo et al., 2013). Since 
stem cell therapy has extended lifespan in animal models of ALS, clinical trials 
are currently ongoing. Glass et al., (2012) reported the results of a Phase I 
clinical trial of injections of human neural stem cells into the lumbar spinal cord of 
ALS patients with lower limb paralysis. The trial showed that the stem cells were 
well tolerated and safe, all patients tolerated the therapy without complications. A 
similar trial is currently recruiting patients, and will begin shortly  
(ClinicalTrials.gov).  A Phase II trial has recently been started by the same 
investigators (Glass et al., 2012), who are transplanting human neural stem cells 
into the lumbar spinal cord of patients with lower limb symptoms, but who were 
not yet paralyzed.  The results of that study have not been reported. Ten of 
eleven patients in the Phase I trial showed either a decline in motor performance 
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or maintenance of their previous level of mobility.  One patient’s symptoms 
improved, however (Glass et al., 2012). 
 
Amyotrophic Lateral Sclerosis does not have a single cause; it is not a single 
disease, rather it is a complex disorder. Many different mutations can cause the 
symptoms (Robberecht et al., 2013), but the cause of most of the prevalent 
sporadic cases has not been elucidated. Stem cell therapy has shown promising 
improvements in the survival of motor neurons, slowing of disease symptoms 
and reduction in motor neuron degeneration in ALS model rodents, and it is 
hoped that transplantation of neural and glial stem cells will also improve the 
lives of ALS patients.  Results from clinical trials to be conducted in the next five 
years should reveal whether stem cell therapy will be a viable treatment for this 
devastating and deadly disease (Ferraiuolo et al., 2013). 
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